Johnson & Johnson $JNJ Shares Sold by Public Employees Retirement System of Ohio

Key Points

• Public Employees Retirement System of Ohio reduced its Johnson & Johnson stake by 7.2% in the second quarter, selling 75,986 shares and retaining 983,704 shares valued at approximately $249.8 million.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $272.83; individual targets range from $280 to $305.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations, reporting $2.90 in EPS and $25.31 billion in revenue, while declaring a quarterly dividend of $1.34 per share.

Public Employees Retirement System of Ohio lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 983,704 shares of the company's stock after selling 75,986 shares during the quarter. Johnson & Johnson accounts for 0.7% of Public Employees Retirement System of Ohio's investment portfolio, making the stock its 17th largest holding. Public Employees Retirement System of Ohio's holdings in Johnson & Johnson were worth $249,831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Elefante Mark B boosted its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after buying an additional 2,563 shares in the last quarter. World Investment Advisors raised its position in Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company's stock worth $33,390,000 after acquiring an additional 26,450 shares in the last quarter. Signal Advisors Wealth LLC raised its position in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock worth $3,697,000 after acquiring an additional 6,539 shares in the last quarter. Gradient Investments LLC lifted its holdings in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after acquiring an additional 13,737 shares during the period. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $30,017,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on JNJ shares. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Scotiabank reissued an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $272.83.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 97,569 shares of company stock worth $25,476,044. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.0%

NYSE:JNJ opened at $275.12 on Tuesday. The company has a market capitalization of $663.01 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $281.07. The stock has a fifty day simple moving average of $262.32 and a 200-day simple moving average of $245.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the prior year, the company earned $2.77 EPS. The firm's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.